Ask Warren

Genome&Company

314130 · KOSDAQ · ₩314130 · 지놈앤컴퍼니

₩3,505▼ ₩135 (3.71%)End-of-day · Oct 30, 2026 · End-of-day prices.
Trade
Alert me
SellBuy
AnnualQuarterly

Income statement

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Revenue₩6.3B₩5.8B₩5.9B₩6.6B₩5.8B₩6.4B₩7.2B₩4.6B
Cost of sales₩2.6B₩2.5B₩2.7B₩3.3B₩2.7B₩2.5B₩3B₩2.8B
Gross profit₩3.6B₩3.3B₩3.2B₩3.2B₩3.2B₩3.9B₩4.2B₩1.8B
Operating income−₩8B−₩6.1B−₩7B−₩8.1B−₩7.4B−₩6.7B−₩5.3B−₩7.8B
Net income−₩43B−₩6.8B₩14B−₩8B−₩6.8B−₩7.1B−₩12B−₩7.2B
Net income to shareholders−₩42B−₩6.3B₩15B−₩7.5B−₩6.4B−₩7.1B−₩6.8B−₩6.8B

Balance sheet

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Total assets₩123B₩174B₩145B₩137B₩142B₩141B₩147B₩152B
Current assets₩79B₩78B₩52B₩64B₩69B₩88B₩92B₩89B
Cash and equivalents₩50B₩47B₩16B₩36B₩43B₩66B₩66B₩58B
Total liabilities₩42B₩60B₩30B₩41B₩40B₩49B₩48B₩50B
Current liabilities₩34B₩53B₩23B₩33B₩23B₩31B₩30B₩29B
Borrowings₩21B₩24B₩15B₩24B₩23B₩28B₩27B₩26B
Total equity₩81B₩114B₩115B₩95B₩102B₩93B₩99B₩102B
Shareholders' equity₩72B₩105B₩106B₩86B₩77B₩42B₩48B₩51B

Cash flow

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Cash from operations−₩3.7B−₩3.1B−₩4.5B−₩6.2B−₩5.5B−₩2.3B−₩4.5B−₩6.7B
Capital spending₩274M₩105M₩80M₩81M₩111M₩13M₩949M₩397M
Free cash flow−₩4B−₩3.3B−₩4.6B−₩6.3B−₩5.6B−₩2.3B−₩5.5B−₩7.1B

Consolidated where available. Amounts in won.

Also known as: Genome&Company / 지놈앤컴퍼니 / 314130 / KRX:314130

Source: KRX statistical information